Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24. On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Trading Up 3.6 %

Shares of CRBP opened at $7.79 on Monday. The company has a market capitalization of $95.29 million, a PE ratio of -1.66 and a beta of 3.19. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $61.90. The stock’s 50-day moving average price is $6.39 and its two-hundred day moving average price is $11.15.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CRBP shares. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. William Blair initiated coverage on shares of Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Jefferies Financial Group reduced their price target on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, Wedbush reissued an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.